ContractCatabasis Pharmaceuticals Inc • January 23rd, 2015 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW, OR SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION CAN BE MADE IN COMPLIANCE WITH RULE 144 OF THE ACT, OR IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 23rd, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ] between Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company,” which term shall include where appropriate, any Entity (as hereinafter defined) controlled by or under the control of Catabasis Pharmaceuticals, Inc.), and [ ] (“Indemnitee”).
CATABASIS PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2008 Equity Incentive PlanNonstatutory Stock Option Agreement • January 23rd, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations
CATABASIS PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2008 Equity Incentive PlanIncentive Stock • January 23rd, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations
CATABASIS PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 23rd, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 31st day of October, 2013, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
